POMC and congenital adrenal hyperplasia: Supraphysiological GC administration, the current standard pharmacotherapy for CAH, aims to suppress the ACTH-driven adrenal hyperandrogenemia with biochemical therapeutic targets that are still higher than the normal reference ranges.